Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- mercaptopurine
- Protopic (tacrolimus topical)
Interactions between your drugs
mercaptopurine tacrolimus topical
Applies to: mercaptopurine, Protopic (tacrolimus topical)
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration of topical tacrolimus with other immunosuppressive agents may potentiate the immunosuppressive effects of topical tacrolimus. However, data concerning its safety and efficacy in combination with immunosuppressants are not available. According to the prescribing information, rare cases of skin malignancy and lymphoma have been reported in patients who have received treatment with topical calcineurin inhibitors, including topical tacrolimus. On the other hand, systemic exposure from topical tacrolimus is reported to be less than 1 ng/mL. In addition, the lowest tacrolimus blood concentration from topical application at which systemic effects can be observed is unknown.
MANAGEMENT: According to the manufacturer, use of topical tacrolimus in immunocompromised patients is not recommended. Therefore, until further information is available, it may be advisable to avoid its concomitant use with other immunosuppressants. Screening for the development of malignancy during and after treatment may also be considered.
Drug and food interactions
mercaptopurine food
Applies to: mercaptopurine
You may experience reduced absorption of mercaptopurine in the presence of food. Take mercaptopurine on an empty stomach 1 hour before or 2 hours after a meal. This will make it easier for your body to absorb the medication.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Blinatumomab
Blinatumomab (Blincyto) is an injectable immunotherapy treatment that may be used to treat B-cell ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.